Upon completion of the activity, participants will demonstrate improved competence and ability to: 

For the Certification Examination in Advanced Heart Failure and Transplant Cardiology:

1. Identify gaps in knowledge about advanced heart failure and transplant cardiology
2. Focus study efforts on filling identified knowledge gaps
3. Practice for the certification examination with ABIM-style multiple-choice test questions

For Clinical Practice:

1. Describe the epidemiology of heart failure, including environmental factors, and implement strategies for the prevention of heart failure
2. Describe the pathophysiology of heart failure, including normal physiology and compensatory and maladaptive mechanisms
3. Assess and follow the patient with acute or advanced heart failure, using non-invasive and invasive tests and biomarkers.
4. Implement guideline-based therapy for patients with chronic heart failure, including pharmacologic agents; non-pharmacologic options, such as diet and exercise; and implantable devices
5. Implement appropriate care strategies for patients undergoing chemotherapy or with pulmonary hypertension, heart failure with preserved ejection fraction, or cardiorenal syndrome.
6. Manage comorbidities in patients with chronic heart failure, including sleep disordered breathing, anemia, and depression
7. Implement strategies for effective disease management of the patient with advanced heart failure, including palliative care and transition to outpatient care
8. Provide peri-operative management of heart failure patients undergoing cardiac transplantation or implantation of a mechanical circulatory device
9. Concise presentations by national experts will focus on blueprint content and will be augmented by board-review type questions posed using an audience-response system.

• Akshay S. Desai, MD, MPH, FHFSA - Brigham and Women’s Hospital, Boston, MA
• Jonathan Rich, MD, FHFSA - Northwestern University, Feinberg School of Medicine, Chicago, IL
• Nancy Sweitzer, MD, PhD, FHFSA - University of Arizona, Tucson, AZ

• Meredith Brisco-Bacik, MD, MSCE - The Lewis Katz School of Medicine at Temple University, Philadelphia, PA
• Daniel Burkhoff, MD, PhD - Columbia University, New York, NY
• Jennifer Cowger, MD, MS - Wayne State University, Detroit, MI
• Akshay S. Desai, MD, MPH, FHFSA - Brigham and Women’s Hospital, Boston, MA
• Mark Drazner, MD, MSc, FHFSA - University of Texas Southwestern Medical Center, Dallas, TX
• James Fang, MD, FHFSA - University of Utah, Salt Lake City, UT
• Sadiya Khan, MD, MSc - Northwestern University Feinberg School of Medicine, Chicago, IL
• Michelle Kittleson, MD, PHD - Cedars Sinai Medical Center, Los Angeles, CA
• Liviu Klein, MD, MS - University of California, San Francisco, San Francisco, CA
• Eric Krieger, MD - University of Washington School of Medicine, Seattle, WA
• Gregory Lewis, MD - Massachusetts General Hospital, Boston, MA
• Jon Lomasney, MD - Feinberg School of Medicine of Northwestern University, Chicago, IL
• Anju Nohria, MD, MSc - Brigham and Women’s Hospital, Boston, MA
• Sean Pinney, MD - The Mount Sinai Hospital, New York, NY
• Jonathan Rich, MD, FHFSA - Northwestern University, Feinberg School of Medicine, Chicago, IL
• Joseph Rogers, MD - Duke University, Durham, NC
• Sanjiv Shah, MD - Northwestern University Feinberg School of Medicine, Chicago, IL
• Nancy Sweitzer, MD, PhD, FHFSA - University of Arizona, Tucson, AZ
• Jane Wilcox, MD, MSc, FHFSA - Bluhm Cardiovascular Institute, Chicago, IL
• Clyde W. Yancy, MD, MSc, FHFSA - Bluhm Cardiovascular Institute, Chicago, IL

Credit Designation

This HFSA Board Review Certification Course has been designed based on the competencies identified with practice in the area of Advanced Heart Failure and Transplant Cardiology.

These competencies include epidemiology, causes and management of patients with HF, management of hospitalized patients, management of comorbidities, cardiac surgery in HF, medical management of the heart transplant patient and patients with mechanical circulatory support, and evaluation and management of patients with pulmonary arterial hypertension.

Physicians

The Heart Failure Society of America is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Heart Failure Society of America designates this live activity for a maximum of 19 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the post course evaluation with a passing score of 80% on the posttests, enables the participant to earn up to 19 MOC points in the Maintenance of Certification (MOC) program. 

Participants of the live virtual activity wishing to claim MOC must complete requirements no later than Monday, November 23, 2020. This will allow time for the HFSA, the CME provider, to submit the participant’s completion information to ACCME for the purpose of granting ABIM MOC credit.

The Heart Failure Society of America (HFSA) is committed to ensuring balance, independence, objectivity, and scientific rigor in its educational activities. HFSA has a disclosure policy that requires oral presenters to disclose all relevant financial relationships for themselves and their spouse or partner during the past 12 months with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients and related to the content of the activity, whether or not these commercial entities are supporters of the activity.

Speakers will have a disclosure slide at the beginning of each presentation. All potential conflicts of interests have been resolved in accordance with the ACCME Updated Standards for Commercial Support.

The following faculty and/or accreditors with ability to control content for this activity have no conflict of interest:

• Meredith Brisco-Bacik, MD, MSCE
• Mark Drazner, MD, MSc, FHFSA
• Sadiya Khan, MD, MSc
• Michelle Kittleson, MD, PHD
• Eric Krieger, MD
• Gregory Lewis, MD
• Jon Lomasney, MD
• Joseph Rogers, MD
• Sanjiv Shah, MD

The following faculty and/or accreditors with ability to control content for this activity have listed the below disclosures:

• Daniel Burkhoff, MD, PhD – Research Grant: Abiomed (Education),Ancora Medical, Tenax,Fire 1; Ownership Interest: PV Loops LLC (non-relevant financial relationship); Consultant-Advisory Board: BackBeat Medical, CardioDyme, Janssen Pharmaceuticals, Medtronic, Axon THerapies; Corvia, PVLoops LLC
• Jennifer Cowger, MD, MS – Research Grant: Abbott, Medtronic; Speaker-Honoraria: Abbott, Medtronic; Consultant-Advisory Board: Abbott, Medtronic
• Akshay Desai, MD, MPH, FHFSA – Research Grant: Alnylam; AstraZeneca; Novartis; Consultant-Advisory Board: Abbott; Alnylam; AstraZeneca; Amgen; Biofourmis; Noston Scientific; Boehringer-Ingelheim; Corvidia; DalCor Pharma; Merck; Novartis; Relypsa; Regeneron
• James C. Fang, MD, FHFSA – Consultant/Advisory Board: Novartis, Amgen, Capricor, Johnson & Johnson, American Heart Association, NIH, AstraZeneca, BI/Lily, Abbott
• Liviu Klein, MD, MS – Consultant-Advisory Board: Boston Scientific (Steering Committee); Medtronic (Steering Committee)
• Anju Nohria, MD, MSc – Research Grant: Amgen, Inc.; Consultant-Advisory Board: Takeda Oncology
• Sean Pinney, MD – Speaker-Honoraria: CareDX; Consultant-Advisory Board: CareDx
• Jonathan D. Rich, MD, FHFSA – Consultant-Advisory Board: Bayer
• Nancy Sweitzer, MD, PhD, FHFSA – Research Grant: Merck, Novartis; Consultant-Advisory Board: Myokardia
• Jane Wilcox, MD, MSc, FHFSA – Speaker-Honoraria: Medtronic; Consultant-Advisory Board: Cytokinetics
• Clyde Yancy, MD, MSc, FHFSA – Financial Disclosure: Spousal employment at Abbott, Inc.

OFF-LABEL DISCLOSURE

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.